GAP Supply Act

The GAP Supply Act amends Section 503B of the Federal Food, Drug, and Cosmetic Act, specifically changing the language from "at the time" to "within 180 calendar days" regarding an outsourcing facility's ability to continue supplying a drug after it enters shortage. This means that once a drug is declared in shortage, outsourcing facilities have an additional 180 days to compound and distribute that drug. This regulatory change provides a critical buffer, allowing these facilities to maintain production and supply lines for an extended period, mitigating immediate revenue loss and providing more consistent supply to the market. The money trail for this bill is indirect but clear: it enables continued revenue generation for outsourcing facilities. These facilities, often contract manufacturers or specialized compounders, will see a reduced risk of immediate cessation of production for drugs in shortage. This regulatory relief translates directly into sustained sales and operational continuity. While no direct appropriations are involved, the bill effectively expands the market window for these facilities during shortage events, increasing their total addressable market for specific drugs. Historically, drug shortages have been a persistent problem, leading to market volatility for affected drugs. For example, during the widespread Adderall shortage in late 2022 and early 2023, manufacturers like Teva Pharmaceutical Industries (not publicly traded in the US under a single ticker, but a major player) faced significant pressure. While this bill does not prevent shortages, it provides a mechanism to soften the financial blow and supply chain disruption for facilities that can respond. There is no direct historical precedent for this specific legislative amendment, but past efforts to streamline drug approval processes or extend patent protections for critical drugs have historically led to increased R&D investment and sustained revenue for pharmaceutical companies. Specific winners are pharmaceutical companies that operate or contract with 503B outsourcing facilities. This includes major pharmaceutical companies that outsource portions of their manufacturing or rely on these facilities for specialized compounding during shortages. Companies like Pfizer ($PFE), Johnson & Johnson ($JNJ), Merck ($MRK), Amgen ($AMGN), Gilead Sciences ($GILD), Eli Lilly ($LLY), Vertex Pharmaceuticals ($VRTX), Biogen ($BIIB), Regeneron Pharmaceuticals ($REGN), and Bristol Myers Squibb ($BMY) all have extensive supply chains that could benefit from this increased flexibility. There are no direct losers, as the bill aims to alleviate supply chain constraints rather than create new ones. This bill has been referred to the House Committee on Energy and Commerce. As the sponsor, Rep. Carter, is a Republican from Georgia, and the bill addresses a non-partisan issue of drug supply, it has a reasonable chance of moving through committee. The next step is committee consideration, potentially followed by a floor vote in the House. If passed, it would then move to the Senate. The timeline for passage is uncertain, but the impact would be immediate upon enactment, providing a 180-day tail period for outsourcing facilities.